Quick Dispatch:
Your hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) ships.
Need Help?
Questions about hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp-1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) in your area.
Hefty $6 Billion Deal: Hengrui Licenses GLP-1 Portfolio to Hercules
25.69
Kailera's three-pronged obesity shot shows promise in early trial
21.42
BMS signs $15.2bn R&D alliance with China's Hengrui
25.35
Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial
20.70
Safiglipron HRS-7535 GLP-1 Receptor Agonist in Kailera IPO Pipeline | Min W. posted on the topic
23.72
GLP-1 drug - Bamboo Works
28.07
$6 Billion GLP-1 Deal Inked Between Hengrui & New U.S. Firm Hercules
26.85
